TransAct Technologies - TACT Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransAct Technologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TACT shares.
View TACT analyst ratings or view top-rated stocks.

1 brokerages have issued 1 year price targets for TransAct Technologies' shares. Their TACT share price forecasts range from $12.00 to $14.00. On average, they predict the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 68.0% from the stock's current price.
View analysts price targets for TACT or view top-rated stocks among Wall Street analysts.

TransAct Technologies' stock was trading at $6.32 at the start of the year. Since then, TACT shares have increased by 19.3% and is now trading at $7.54.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our TACT earnings forecast.

TransAct Technologies Incorporated (NASDAQ:TACT) announced its quarterly earnings data on Thursday, November, 10th. The technology company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.26. The technology company had revenue of $17.86 million for the quarter, compared to analyst estimates of $14.90 million. TransAct Technologies had a negative net margin of 12.86% and a negative trailing twelve-month return on equity of 22.18%.

6 employees have rated TransAct Technologies Chief Executive Officer Bart C. Shuldman on Glassdoor.com. Bart C. Shuldman has an approval rating of 22% among the company's employees. This puts Bart C. Shuldman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransAct Technologies investors own include Allena Pharmaceuticals (ALNA), Energy Transfer (ET), Palatin Technologies (PTN), RedHill Biopharma (RDHL), Veru (VERU), British American Tobacco (BTI), Cerecor (CERC), Enterprise Products Partners (EPD), Genocea Biosciences (GNCA) and Intel (INTC).

TransAct Technologies trades on the NASDAQ under the ticker symbol "TACT."

TransAct Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include 325 Capital Llc, Andrew John Hoffman, B Riley Financial, Inc, Bart C Shuldman, Haydee Olinger, Raymond T Walsh Jr and Steven A Demartino.
View institutional ownership trends.

Shares of TACT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TACT stock can currently be purchased for approximately $7.54.

TransAct Technologies (NASDAQ:TACT) has a market capitalization of $74.72 million and generates $39.39 million in revenue each year. The technology company earns $-4,140,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

The company employs 118 workers across the globe.

TransAct Technologies' mailing address is ONE HAMDEN CENTER 2319 WHITNEY AVENUE SUITE 3B, HAMDEN CT, 06518. The official website for the company is www.transact-tech.com. The technology company can be reached via phone at (203) 859-6800, via email at tact@jcir.com, or via fax at 203-949-9048.